In Vivo's Deals Of The Month, September 2016

Sanofi and Verily Life Sciences will invest $500 million in their new joint venture Onduo, which will develop integrated treatment and monitoring solutions for diabetes. [See Deal] Onduo will operate independently from its creators, but can draw on their resources as well as those from outside partners. With the first product expected on the market within two to three years, Onduo CEO Joshua Riff, MD, envisions using Sanofi's drug expertise and Verily's knowledge of miniature electronics, analytics and consumer software development to create delivery and monitoring technologies that give type 2 (and eventually type 1) patients the ability to better manage their disease. The joint venture is the second in as many months for Verily, whose Galvani Bioelectronics neuromodulation JV with GlaxoSmithKline PLC was our pick for top alliance in August. [See Deal]